Van ECK Associates Corp Invests $2.96 Million in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Van ECK Associates Corp bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 36,868 shares of the medical equipment provider's stock, valued at approximately $2,960,000. Van ECK Associates Corp owned about 0.05% of Lantheus as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. International Assets Investment Management LLC purchased a new stake in Lantheus during the 4th quarter valued at $407,000. M&T Bank Corp purchased a new stake in Lantheus during the 4th quarter valued at $320,000. Charles Schwab Investment Management Inc. raised its holdings in Lantheus by 0.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 839,957 shares of the medical equipment provider's stock valued at $52,077,000 after buying an additional 7,590 shares during the period. Principal Securities Inc. purchased a new stake in Lantheus during the 4th quarter valued at $28,000. Finally, Versor Investments LP purchased a new stake in Lantheus during the 4th quarter valued at $506,000. 99.06% of the stock is currently owned by institutional investors.

Lantheus Stock Performance

Shares of NASDAQ:LNTH traded down $3.36 during trading on Friday, hitting $101.98. The stock had a trading volume of 548,069 shares, compared to its average volume of 1,036,350. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89. The stock has a market capitalization of $7.07 billion, a price-to-earnings ratio of 15.57 and a beta of 0.51. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. The stock has a 50-day simple moving average of $102.61 and a two-hundred day simple moving average of $81.26.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm had revenue of $394.10 million during the quarter, compared to analysts' expectations of $382.12 million. During the same quarter in the previous year, the business earned $1.40 earnings per share. The company's revenue for the quarter was up 22.5% compared to the same quarter last year. On average, equities research analysts expect that Lantheus Holdings, Inc. will post 6.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LNTH has been the topic of several recent research reports. Redburn Atlantic began coverage on Lantheus in a report on Tuesday. They set a "buy" rating and a $175.00 price target on the stock. JMP Securities reduced their target price on Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 1st. B. Riley increased their target price on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research note on Thursday, July 25th. Truist Financial reduced their target price on Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a research note on Thursday, August 1st. Finally, Leerink Partners increased their target price on Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a research note on Thursday, July 11th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $126.00.

Insider Activity at Lantheus

In related news, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $79.77, for a total transaction of $27,201.57. Following the completion of the transaction, the chief accounting officer now directly owns 62,557 shares in the company, valued at $4,990,171.89. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Mary Anne Heino sold 10,481 shares of the business's stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $95.50, for a total value of $1,000,935.50. Following the completion of the sale, the director now directly owns 454,923 shares in the company, valued at $43,445,146.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Andrea Sabens sold 341 shares of the business's stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $79.77, for a total value of $27,201.57. Following the completion of the sale, the chief accounting officer now owns 62,557 shares of the company's stock, valued at $4,990,171.89. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,193 shares of company stock worth $3,949,202. 1.50% of the stock is owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.